Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 10/20 | 0.64 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.52 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.52 |
| ▸ | PDE4A | P27815 | 2/20 | 0.52 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.52 |
| ▸ | KDM1A | O60341 | 1/20 | 0.46 |
| ▸ | TOP2A | P11388 | 1/20 | 0.44 |
| ▸ | DPP4 | P27487 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23373812 | 0.87 | GPR119 (0.60) | GPR119PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL2776116 | 0.86 | GPR119 (0.69) | GPR119PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL15567098 | 0.85 | GPR119 (0.67) | GPR119PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL223707 | 0.85 | GPR119 (0.45) | GPR119PDE4B | |
| SCHEMBL5971305 | 0.84 | GPR119 (0.66) | GPR119PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL17008808 | 0.84 | GPR119 (0.66) | GPR119PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL13718678 | 0.84 | GPR119 (0.66) | GPR119PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL16818268 | 0.83 | GPR119 (0.65) | GPR119PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL3850739 | 0.82 | GPR119 (0.64) | GPR119PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL17009591 | 0.82 | GPR119 (0.64) | GPR119PDE4DPDE4BPDE4APDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230017597-A1 | 8-SUBSTITUTED STYRYL XANTHINE DERIVATIVES AND USES THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2023-01-19 | — | — | US | disclosed |
| US-20230017597-A1 | 8-SUBSTITUTED STYRYL XANTHINE DERIVATIVES AND USES THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2023-01-19 | — | — | US | disclosed |
| CN-112300165-B | 8-substituted styrylxanthine derivatives and uses thereof | 广东东阳光药业有限公司 | 2022-03-04 | — | — | CN | disclosed |
| WO-2021093701-A1 | 8-SUBSTITUTED STYRYL XANTHINE DERIVATIVES AND USES THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2021-05-20 | — | — | WO | disclosed |
| CN-112300165-A | 8-substituted styrylxanthine derivatives and uses thereof | 广东东阳光药业有限公司 | 2021-02-02 | — | — | CN | disclosed |
| EP-1577288-B1 | Selective estrogen receptor modulators | EISAI R&D MAN CO LTD (JP) | 2014-07-23 | — | — | EP | disclosed |
| US-8399520-B2 | Selective estrogen receptor modulator | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-03-19 | — | — | US | disclosed |
| US-8399520-B2 | Selective estrogen receptor modulator | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-03-19 | — | — | US | disclosed |
| US-8399520-B2 | Selective estrogen receptor modulator | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-03-19 | — | — | US | disclosed |
| US-20120004315-A1 | Selective Estrogen Receptor Modulator | RADIUS HEALTH, INC. | 2012-01-05 | — | — | US | disclosed |
| US-7960412-B2 | Selective estrogen receptor modulator | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-06-14 | — | — | US | disclosed |
| US-7960412-B2 | Selective estrogen receptor modulator | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-06-14 | — | — | US | disclosed |
| US-20090325930-A1 | SELECTIVE ESTROGEN RECEPTOR MODULATOR | RADIUS HEALTH, INC. | 2009-12-31 | — | — | US | disclosed |
| US-20090325930-A1 | SELECTIVE ESTROGEN RECEPTOR MODULATOR | RADIUS HEALTH, INC. | 2009-12-31 | — | — | US | disclosed |
| US-20090325930-A1 | SELECTIVE ESTROGEN RECEPTOR MODULATOR | RADIUS HEALTH, INC. | 2009-12-31 | — | — | US | disclosed |
| US-7612114-B2 | Such as (R)-6-{2-{ethyl[4-(2-ethylaminoethyl)benzyl]amino }-4-methoxyphenyl }-5,6,7,8-tetrahydronaphthalen-2-ol; osteoporosis; breast cancer | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-11-03 | — | — | US | disclosed |
| US-7612114-B2 | Such as (R)-6-{2-{ethyl[4-(2-ethylaminoethyl)benzyl]amino }-4-methoxyphenyl }-5,6,7,8-tetrahydronaphthalen-2-ol; osteoporosis; breast cancer | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-11-03 | — | — | US | disclosed |
| US-7612114-B2 | Such as (R)-6-{2-{ethyl[4-(2-ethylaminoethyl)benzyl]amino }-4-methoxyphenyl }-5,6,7,8-tetrahydronaphthalen-2-ol; osteoporosis; breast cancer | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-11-03 | — | — | US | disclosed |
| US-20060116364-A1 | Such as (R)-6-{2-{ethyl[4-(2-ethylaminoethyl)benzyl]amino }-4-methoxyphenyl }-5,6,7,8-tetrahydronaphthalen-2-ol; osteoporosis; breast cancer | EISAI CO., LTD. (JP) | 2006-06-01 | — | — | US | disclosed |
| EP-1577288-A1 | SELECTIVE ESTROGEN RECEPTOR MODULATORS | Eisai Co., Ltd. (JP) | 2005-09-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325930-A1 | SELECTIVE ESTROGEN RECEPTOR MODULATOR | ESR1, GPER1, ESR2 | GPR119 225/4885PDE4D 4790/4885PDE4B 4739/4885 |
| US-20230017597-A1 | 8-SUBSTITUTED STYRYL XANTHINE DERIVATIVES AND USES THEREOF | ADORA2A, ADORA3, ADORA2B | GPR119 287/4885PDE4D 34/4885PDE4B 31/4885 |
| US-20060116364-A1 | Such as (R)-6-{2-{ethyl[4-(2-ethylaminoethyl)benzyl]amino }-4-methoxyphenyl }-5,6,7,8-tetrahydronaphthalen-2-ol; osteoporosis; breast cancer | BRCA1, BCR, RCC1 | GPR119 1708/4885PDE4D 4868/4885PDE4B 4864/4885 |
| US-20120004315-A1 | Selective Estrogen Receptor Modulator | ESR1, GPER1, ESR2 | GPR119 346/4885PDE4D 4792/4885PDE4B 4756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.